Last reviewed · How we verify
Norigest (norethindrone enanthate)
Norigest (generic name: norethindrone enanthate) is a Progestin drug. It is currently in unknown development.
Norigest works by binding to progesterone receptors in the body, mimicking the effects of the hormone progesterone.
Norigest (norethindrone enanthate) is a progestin medication, a small molecule that belongs to the class of progestins. It is used to treat conditions such as endometriosis and fibrocystic breast disease. The commercial status of Norigest is unknown, and it is not clear if it is patented or available as a generic medication. As a progestin, Norigest works by mimicking the effects of progesterone in the body, which can help to regulate the menstrual cycle and reduce symptoms of certain conditions. However, more information is needed to provide a comprehensive summary.
At a glance
| Generic name | norethindrone enanthate |
|---|---|
| Drug class | Progestin |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's hormones as a key and lock system. Progesterone is a key that helps regulate the menstrual cycle and other bodily functions. Norigest is a similar key that fits into the same lock, helping to calm down the body's reproductive system and reduce symptoms of certain conditions.
Approved indications
Common side effects
Key clinical trials
- PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.
- Effects of One-to-one Service on the Continuation and Satisfaction of Contraceptive Use. (NA)
- HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC
- The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis (PHASE4)
- A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods (NA)
- Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norigest CI brief — competitive landscape report
- Norigest updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Norigest
What is Norigest?
How does Norigest work?
What is the generic name of Norigest?
What drug class is Norigest in?
What development phase is Norigest in?
Related
- Drug class: All Progestin drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing